Polymorph of chlorpyrifos and its preparation method and application

By optimizing the polycrystalline substance preparation process of toxic fluorine phosphorus, the shortcomings of toxic fluorine phosphorus in dissolution performance and stability are solved, and an efficient anti-plant virus agent is formed, which significantly improves the prevention and treatment effect of specific plant viruses and is suitable for Industrialized production.

CN112500432BActive Publication Date: 2024-11-26EAST CHINA UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201910872370.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-09-16
Publication Date
2024-11-26
Estimated Expiration
2039-09-16

AI Technical Summary

Technical Problem

The existing toxic fluorine phosphorus products have shortcomings in their dissolution performance and stability, making it difficult to effectively prevent and control plant viruses, especially the prevention and treatment of rice black stripe dwarf and tomato virus disease.

Method used

By preparing polycrystalline substances such as crystal forms B, C, D, E and F, different process methods such as heating, suspension, dissolution and ultrasonic methods are used to optimize process conditions to improve their dissolution performance and stability. and combined with pesticideally acceptable carriers to form an anti-plant viral agent.

Benefits of technology

It has achieved excellent dissolution performance and stability of toxic fluorine phosphorus polycrystalline substances, significantly improved the prevention and treatment effect of rice black stripe dwarf and tomato virus disease, is suitable for large-scale industrial production, and enhanced the disease resistance of plants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure BDA0002203224370000021
    Figure BDA0002203224370000021
  • Figure BDA0002203224370000164
    Figure BDA0002203224370000164
Patent Text Reader

Abstract

The present invention relates to polymorphs of chlorpyrifos and a preparation method and application thereof. Specifically, the present invention discloses five polymorphs of chlorpyrifos and a preparation method thereof, wherein the polymorphs have excellent stability and solubility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of pharmaceutical chemistry, and in particular to a polymorph of chlorpyrifos and a preparation method and application thereof. Background Art

[0002] The harm of plant viruses to their hosts is known as "plant cancer", and prevention and control is very difficult. After infecting the host, the virus not only competes with the host for the nutrients necessary for growth, but also destroys the plant's nutrient transport, changes certain metabolic balances of the host plant, inhibits the plant's photosynthesis, makes it difficult for the plant to grow, produces symptoms such as deformity and yellowing, and in severe cases causes the death of the host plant.

[0003] Phosphate (compound of formula I), namely The chemical name is N-[2-(4-methylbenzothiazolyl)]-2-amino-2'-fluorophenyl-O,O-diethylphosphonate, which is an anti-plant virus agent independently developed in my country. A large number of experiments have shown that it has excellent control effects on tobacco mosaic disease, rice black streak virus disease, and tomato virus disease. The agent is environmentally friendly, has a simple production process, does not pollute the three wastes, and can also improve plant disease resistance. Summary of the invention

[0004] The object of the present invention is to provide a polymorph of chlorpyrifos with excellent solubility and stability, and a preparation method and application thereof.

[0005] In a first aspect of the present invention, there is provided a polymorph of a compound represented by formula (I), wherein the polymorph is selected from the group consisting of Form B, Form C, Form D, Form E, Form F,

[0006]

[0007] The X-ray powder diffraction pattern of the crystalline form B has diffraction peaks at the following 2θ values: 11.9±0.2°, 14.9±0.2°, 17.3±0.2°, 20.3±0.2°, 22.4±0.2°, 22.7±0.2°;

[0008] The X-ray powder diffraction pattern of the crystalline form C has diffraction peaks at the following 2θ values: 12.2±0.2°, 16.3±0.2°, 21.6±0.2°, 23.5±0.2°, 24.0±0.2°, 30.9±0.2°;

[0009] The X-ray powder diffraction pattern of the crystalline form D has diffraction peaks at the following 2θ values: 9.3±0.2°, 11.4±0.2°, 19.9±0.2°, 21.3±0.2°, 22.3±0.2°, 25.2±0.2°;

[0010] The X-ray powder diffraction pattern of the crystalline form E has diffraction peaks at the following 2θ values: 9.3±0.2°, 10.3±0.2°, 13.3±0.2°, 17.6±0.2°, 25.8±0.2°, 32.1±0.2°;

[0011] The X-ray powder diffraction pattern of the crystalline form F has diffraction peaks at the following 2θ values: 8.6±0.2°, 15.1±0.2°, 16.2±0.2°, 17.4±0.2°, 17.6±0.2°, and 22.7±0.2°.

[0012] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B also has diffraction peaks at 1, 2, 3, 4, 5 or 6 2θ values ​​selected from the following group: 8.7±0.2°, 9.3±0.2°, 16.2±0.2°, 18.9±0.2°, 19.8±0.2°, 21.4±0.2°.

[0013] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B includes 6 or more 2θ values ​​selected from the following group: 8.7±0.2°, 9.3±0.2°, 11.9±0.2°, 14.9±0.2°, 16.2±0.2°, 17.3±0.2°, 18.9±0.2°, 19.8±0.2°, 20.3±0.2°, 21.4±0.2°, 22.4±0.2°, 22.7±0.2°, 24.1±0.2°, 26.4±0.2°, and 27.1±0.2°.

[0014] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B includes 9 or more 2θ values ​​selected from the following group: 8.7±0.2°, 9.3±0.2°, 11.9±0.2°, 14.9±0.2°, 16.2±0.2°, 17.3±0.2°, 18.9±0.2°, 19.8±0.2°, 20.3±0.2°, 21.4±0.2°, 22.4±0.2°, 22.7±0.2°, 24.1±0.2°, 26.4±0.2°, and 27.1±0.2°.

[0015] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B includes 12 or more 2θ values ​​selected from the following group: 8.7±0.2°, 9.3±0.2°, 11.9±0.2°, 14.9±0.2°, 16.2±0.2°, 17.3±0.2°, 18.9±0.2°, 19.8±0.2°, 20.3±0.2°, 21.4±0.2°, 22.4±0.2°, 22.7±0.2°, 24.1±0.2°, 26.4±0.2°, and 27.1±0.2°.

[0016] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B includes 9 or more 2θ values ​​selected from the following group: 8.7±0.2°, 9.3±0.2°, 9.8±0.2°, 11.9±0.2°, 12.5±0.2°, 12.9±0.2°, 13.3±0.2°, 14.9±0.2°, 16.2±0.2°, 17.3±0.2°, 1 8.0±0.2°, 18.4±0.2°, 18.9±0.2°, 19.8±0.2°, 20.3±0.2°, 21.4±0.2°, 22.0±0.2°, 22.4±0.2°, 22.7±0.2°, 24.1±0.2°, 24.8±0.2°, 25.2±0.2°, 26.4±0.2°, 27.1±0.2°.

[0017] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B includes 12 or more 2θ values ​​selected from the following group: 8.7±0.2°, 9.3±0.2°, 9.8±0.2°, 11.9±0.2°, 12.5±0.2°, 12.9±0.2°, 13.3±0.2°, 14.9±0.2°, 16.2±0.2°, 17.3±0.2°, 18.0±0.2°, 18.4±0.2°, 18.9±0.2°, 19.8±0.2°, 20.3±0.2°, 21.4±0.2°, 22.0±0.2°, 22.4±0.2°, 22.7±0.2°, 24.1±0.2°, 24.8±0.2°, 25.2±0.2°, 26.4±0.2°, 27.1±0.2°.

[0018] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B includes 15 or more 2θ values ​​selected from the following group: 8.7±0.2°, 9.3±0.2°, 9.8±0.2°, 11.9±0.2°, 12.5±0.2°, 12.9±0.2°, 13.3±0.2°, 14.9±0.2°, 16.2±0.2°, 17.3±0.2°, 18.0±0.2°, 18.4±0.2°, 18.9±0.2°, 19.8±0.2°, 20.3±0.2°, 21.4±0.2°, 22.0±0.2°, 22.4±0.2°, 22.7±0.2°, 24.1±0.2°, 24.8±0.2°, 25.2±0.2°, 26.4±0.2°, 27.1±0.2°.

[0019] In another preferred embodiment, the “6 or more” refers to an integer of 6-15, specifically as follows: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15.

[0020] In another preferred embodiment, the 2θ value of the X-ray powder diffraction pattern of the crystal form has a deviation of ±0.5, preferably a deviation of ±0.3, and more preferably a deviation of ±0.1.

[0021] In another preferred embodiment, the crystalline form B has one or more characteristics selected from the following group:

[0022] 1) The X-ray powder diffraction pattern of the crystalline form B is substantially as follows Figure 1 As shown;

[0023] 2) The DSC graph of the crystal form B has an endothermic peak in the range of 155 to 165°C;

[0024] 3) The DSC diagram of the crystal form B is basically as follows Figure 2 As shown;

[0025] 4) The TG diagram of the crystal form B is basically as follows Figure 3 As shown;

[0026] 5) At 25° C., the solubility of the crystalline form B in n-hexane is ≥1 mg / mL.

[0027] In another preferred embodiment, the purity of Form B is greater than 95%, preferably, the purity is greater than 97%, more preferably, the purity is greater than 99%, and most preferably, the purity is greater than 99.5%.

[0028] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form C also has diffraction peaks at 1, 2, 3, 4, 5 or 6 2θ values ​​selected from the following group: 12.8±0.2°, 14.2±0.2°, 17.7±0.2°, 18.9±0.2°, 20.3±0.2°, 26.1±0.2°.

[0029] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form C includes 3 or more 2θ values ​​selected from the following group: 9.4±0.2°, 12.2±0.2°, 12.8±0.2°, 13.1±0.2°, 14.2±0.2°, 16.3±0.2°, 17.7±0.2°, 18.4±0.2°, 18.9±0.2°, 19.5±0.2°, 19.8±0.2°, 20.3±0.2°, 21.6±0.2°, 22.2±0.2°, 23.5±0.2°, 24.0±0.2°, 25.9±0.2°, 26.1±0.2°, 30.9±0.2°, 34.4±0.2°, 34.7±0.2°, 41.6±0.2°.

[0030] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form C includes 3 or more (such as 6, 9, 12, 15) 2θ values ​​selected from the following group: 6.6±0.2°, 9.4±0.2°, 10.1±0.2°, 11.6±0.2°, 12.2±0.2°, 12.8±0.2°, 13.1±0.2°, 14.2±0.2°, 14.5±0 .2°, 15.5±0.2°, 16.3±0.2°, 17.7±0.2°, 18.4±0.2°, 18.9±0.2°, 19.5±0.2°, 19.8±0.2°, 20.3±0.2°, 21.6±0.2°, 22.2±0.2°, 23.5±0.2°, 24.0±0.2°, 24.6±0.2°, 25.1±0. 2°, 25.9±0.2°, 26.1±0.2°, 26.6±0.2°, 27.1±0.2°, 27.7±0.2°, 28.5±0.2°, 28.9±0.2°, 29.7±0.2°, 30.1±0.2°, 30.9±0.2°, 31.3±0.2°, 31.7±0.2°, 32.9±0.2°, 34.4±0.2 °, 34.7±0.2°, 35.7±0.2°, 36.3±0.2°, 36.5±0.2°, 37.3±0.2°, 37.9±0.2°, 39.0±0.2°, 40.6±0.2°, 41.3±0.2°, 41.6±0.2°, 42.5±0.2°, 42.8±0.2°, 43.9±0.2°, 44.5±0.2°.

[0031] In another preferred embodiment, the crystalline form C has one or more characteristics selected from the following group:

[0032] 1) The X-ray powder diffraction pattern of the crystalline form C is substantially as follows Fig.17 As shown;

[0033] 2) The DSC graph of the crystal form C has an endothermic peak in the range of 143-153°C;

[0034] 3) The DSC diagram of the crystal form C is basically as follows Fig.18 As shown;

[0035] 4) The TG diagram of the crystal form C is basically as follows Fig.19 shown.

[0036] In another preferred embodiment, the purity of Form C is greater than 95%, preferably, the purity is greater than 97%, more preferably, the purity is greater than 99%, and most preferably, the purity is greater than 99.5%.

[0037] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form D also has diffraction peaks at 1, 2, 3, 4, 5 or 6 2θ values ​​selected from the following group: 14.7±0.2°, 16.1±0.2°, 16.8±0.2°, 20.8±0.2°, 22.9±0.2°, 24.0±0.2°.

[0038] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form D includes 3 or more (such as 6, 9, 12, 15) 2θ values ​​selected from the following group: 7.6±0.2°, 9.3±0.2°, 11.4±0.2°, 14.7±0.2°, 15.2±0.2°, 16.1±0.2°, 16.6±0.2°, 16.8±0.2°, 18.1±0.2°, 18.5±0.2°, 19.9±0.2°, 20 .8±0.2°, 21.3±0.2°, 21.5±0.2°, 22.3±0.2°, 22.9±0.2°, 24.0±0.2°, 24.4±0.2°, 24.7±0.2°, 25.2±0.2°, 27.6±0.2°, 28.1±0.2°, 28.4±0.2°, 30.3±0.2°, 30.7±0.2°, 32.5±0.2°, 34.6±0.2°, 35.8±0.2°.

[0039] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form D includes 3 or more (such as 6, 9, 12, 15) 2θ values ​​selected from the following group: 7.6±0.2°, 8.6±0.2°, 9.3±0.2°, 11.4±0.2°, 13.2±0.2°, 14.7±0.2°, 15.2±0.2°, 16.1±0.2°, 16.6±0.2°, 16.8 ±0.2°, 17.2±0.2°, 18.1±0.2°, 18.5±0.2°, 19.9±0.2°, 20.8±0.2°, 21.3±0.2°, 21.5±0.2°, 22.3±0.2°, 22.9±0.2°, 23.6±0.2°, 24.0±0.2°, 24.4±0.2°, 24.7±0.2°, 25.2±0.2°, 26. 6±0.2°, 27.2±0.2°, 27.6±0.2°, 28.1±0.2°, 28.4±0.2°, 29.0±0.2°, 29.7±0.2°, 30.3±0.2°, 30.7±0.2°, 31.0±0.2°, 32.5±0.2°, 32.9±0.2°, 33.4±0.2°, 34.2±0.2°, 34.6±0.2°, 3 5.0±0.2°, 35.8±0.2°, 36.2±0.2°, 36.5±0.2°, 37.4±0.2°, 38.0±0.2°, 38.6±0.2°, 39.3±0.2°, 39.7±0.2°, 40.1±0.2°, 40.6±0.2°, 41.1±0.2°, 42.1±0.2°, 43.5±0.2°, 44.5±0.2°.

[0040] In another preferred embodiment, the crystalline form D has one or more characteristics selected from the following group:

[0041] 1) The X-ray powder diffraction pattern of the crystal form D is substantially as follows Fig. 20 As shown;

[0042] 2) The DSC graph of the crystal form D has a solvent endothermic peak in the range of 70-110°C;

[0043] 3) The DSC diagram of the crystal form D is basically as follows Fig.21 As shown;

[0044] 4) The TG diagram of the crystal form D is basically as follows Fig. 22 shown.

[0045] In another preferred embodiment, the purity of Form D is greater than 95%, preferably, the purity is greater than 97%, more preferably, the purity is greater than 99%, and most preferably, the purity is greater than 99.5%.

[0046] In another preferred embodiment, the crystalline form D is a 1,4-dioxane solvate.

[0047] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form E also has diffraction peaks at 1, 2, 3, 4, 5 or 6 2θ values ​​selected from the following group: 13.0±0.2°, 15.9±0.2°, 17.8±0.2°, 19.0±0.2°, 20.8±0.2°, 23.6±0.2°.

[0048] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form E includes 3 or more (such as 6, 9, 12, 15) 2θ values ​​selected from the following group: 9.3±0.2°, 10.3±0.2°, 10.5±0.2°, 13.0±0.2°, 13.3±0.2°, 15.9±0.2°, 16.1±0.2°, 17.6±0.2°, 17 .8±0.2°, 19.0±0.2°, 20.8±0.2°, 21.3±0.2°, 22.2±0.2°, 23.6±0.2°, 24.2±0.2°, 25.8±0.2°, 26.9±0.2°, 27.1±0.2°, 27.3±0.2°, 32.1±0.2°, 34.8±0.2°, 36.9±0.2°.

[0049] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form E includes 3 or more (such as 6, 9, 12, 15) 2θ values ​​selected from the following group: 9.3±0.2°, 10.3±0.2°, 10.5±0.2°, 13.0±0.2°, 13.3±0.2°, 15.9±0.2°, 16.1±0.2°, 16.4±0.2°, 17.1±0.2°, 17.6±0.2°, 17.8±0.2°, 19.0±0.2°, 20.8±0.2°, 21.3±0.2°, 22.2±0.2°, 23.6±0.2°. 0.2°, 24.2±0.2°, 25.8±0.2°, 26.9±0.2°, 27.1±0.2°, 27.3±0.2°, 28.3±0.2°, 29.1±0.2°, 29.7±0.2°, 31.0±0.2°, 32.1±0.2°, 34.8±0.2°, 36.2±0.2°, 36.5±0.2°, 36.9±0.2°, 37.5±0.2°, 38.3±0.2°, 39.0±0.2°, 42.2±0.2°, 42.7±0.2°, 43.1±0.2°, 44.3±0.2°.

[0050] In another preferred embodiment, the crystalline form E has one or more characteristics selected from the following group:

[0051] 1) The X-ray powder diffraction pattern of the crystalline form E is substantially as follows Fig.23 As shown;

[0052] 2) The DSC graph of the crystal form E has an endothermic peak in the range of 128-136°C;

[0053] 3) The DSC diagram of the crystal form E is basically as follows Fig.24 As shown;

[0054] 4) The TG diagram of the crystal form E is basically as follows Fig.25 shown.

[0055] In another preferred embodiment, the purity of Form E is greater than 95%, preferably, the purity is greater than 97%, more preferably, the purity is greater than 99%, and most preferably, the purity is greater than 99.5%.

[0056] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form F also has diffraction peaks at 1, 2, 3, 4, 5 or 6 2θ values ​​selected from the following group: 11.8±0.2°, 13.0±0.2°, 14.6±0.2°, 20.2±0.2°, 21.0±0.2°, 26.2±0.2°.

[0057] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form F includes 3 or more (such as 6, 9, 12, 15) 2θ values ​​selected from the following group: 8.6±0.2°, 10.3±0.2°, 10.7±0.2°, 11.8±0.2°, 12.2±0.2°, 13.0±0.2°, 14.6±0.2°, 15.1±0.2°, 16.2±0.2°, 16.7±0. 2°, 17.4±0.2°, 17.6±0.2°, 18.5±0.2°, 19.2±0.2°, 20.2±0.2°, 20.6±0.2°, 21.0±0.2°, 22.7±0.2°, 26.2±0.2°, 27.3±0.2°, 28.0±0.2°, 31.0±0.2°, 36.7±0.2°, 37.2±0.2°, and 39.5±0.2°.

[0058] In another preferred embodiment, the X-ray powder diffraction pattern of the crystalline form F includes 3 or more (such as 6, 9, 12, 15) 2θ values ​​selected from the following group: 8.1±0.2°, 8.6±0.2°, 9.2±0.2°, 10.3±0.2°, 10.7±0.2°, 11.8±0.2°, 12.2±0.2°, 13.0±0. 2°, 13.6±0.2°, 14.6±0.2°, 15.1±0.2°, 16.2±0.2°, 16.7±0.2°, 17.4±0.2°, 17.6±0.2°, 18.5±0.2°, 19.2±0.2°, 19.6±0.2°, 20.2±0.2°, 20.6±0.2°, 21.0±0.2 °, 21.6±0.2°, 22.7±0.2°, 23.4±0.2°, 24.2±0.2°, 24.7±0.2°, 26.2±0.2°, 27.3±0.2°, 27.8±0.2°, 28.0±0.2°, 28.9±0.2°, 29.6±0.2°, 31.0±0.2°, 32.9±0.2° , 33.4±0.2°, 34.3±0.2°, 34.9±0.2°, 35.6±0.2°, 36.7±0.2°, 37.2±0.2°, 39.1±0.2°, 39.5±0.2°, 40.0±0.2°, 41.2±0.2°, 41.8±0.2°, 43.0±0.2°, 44.6±0.2°.

[0059] In another preferred embodiment, the crystalline form F has one or more characteristics selected from the following group:

[0060] 1) The X-ray powder diffraction pattern of the crystalline form F is substantially as follows Fig.26 As shown;

[0061] 2) The DSC graph of the crystal form F has an endothermic peak in the range of 152-162°C;

[0062] 3) The DSC diagram of the crystal form F is basically as follows Fig. 27 As shown;

[0063] 4) The TG diagram of the crystal form F is basically as follows Fig.28 shown.

[0064] In another preferred embodiment, the purity of the crystalline form F is greater than 95%, preferably, the purity is greater than 97%, more preferably, the purity is greater than 99%, and most preferably, the purity is greater than 99.5%.

[0065] The second aspect of the present invention provides a pesticide composition, the composition comprising:

[0066] (a) one or more polymorphs according to the first aspect of the present invention, and

[0067] (b) A pesticide-acceptable carrier.

[0068] The third aspect of the present invention provides a method for preparing the polymorph described in the first aspect of the present invention, wherein the method is selected from the following group:

[0069] Method 1: A method for preparing Form B, comprising the steps of:

[0070] 1-1) providing an amorphous form of the compound represented by formula (I);

[0071] 1-2) heat treating the amorphous phase at 150-160° C. and cooling to obtain the crystalline form B;

[0072] Method 2: A method for preparing Form C, comprising the steps of:

[0073] 2-1) mixing the amorphous form of the compound represented by formula (I) and solvent A;

[0074] 2-2) suspending and treating at 4-40° C. (preferably 15-30° C.) for 0.1-24 h (preferably 0.1-0.5 h), filtering and drying to obtain the crystalline form C;

[0075] Method 3: A method for preparing Form C, comprising the steps of:

[0076] 3-1) mixing the compound represented by formula (I) and solvent B to obtain a mixture B;

[0077] 3-2) adding solvent C to mixture B, standing at 0-40° C. (preferably 4-30° C.) for volatilization for 5-50 h (preferably 8-40 h), and drying to obtain the crystalline form C;

[0078] Method 4: A method for preparing Form D, comprising the steps of:

[0079] 4-1) mixing the compound represented by formula (I) and 1,4-dioxane;

[0080] 4-2) suspending and stirring at 4-40° C. (preferably 15-30° C.) for 1-24 h (preferably 5-16 h), filtering and drying to obtain the crystalline form D;

[0081] Method 5: A method for preparing Form E, comprising the steps of:

[0082] 5-1) mixing the amorphous form of the compound represented by formula (I) and a chloroform solvent;

[0083] 5-2) after ultrasonic treatment for 0.5-5h, standing at 4-40°C for 2-24h for volatilization, and drying to obtain the crystal form E;

[0084] Method 6: A method for preparing Form E, comprising the steps of:

[0085] 6-1) mixing the compound represented by formula (I) and solvent D to obtain a mixture D;

[0086] 6-2) adding isopropyl ether to the mixture D, standing at 4-40° C. for 2-24 hours for volatilization, and drying to obtain the crystalline form E;

[0087] Method 7: A method for preparing Form F, comprising the steps of:

[0088] 7-1) mixing the amorphous form of the compound represented by formula (I) and a toluene solvent;

[0089] 7-2) after ultrasonic treatment for 0.5-5h, standing at 4-40°C for 2-24h for volatilization, and drying to obtain the crystal form F;

[0090] Method 8: A method for preparing Form F, comprising the steps of:

[0091] 8-1) mixing the compound represented by formula (I) and acetone solvent to obtain a mixture E;

[0092] 8-2) Add ethylene glycol to the mixture E, let stand at 4-40° C. for 2-24 h, filter and dry to obtain the crystalline form F.

[0093] In another preferred embodiment, in step 1-2), the heat treatment time is 5-60 min, preferably 15-40 min.

[0094] In another preferred embodiment, solvent A is selected from the following group: methanol, ethanol, a mixture of methanol and water, and a mixture of ethanol and water.

[0095] In another preferred embodiment, in step 2-1), the ratio of the mass of the amorphous phase to the volume of the solvent A is 100-300 mg / ml.

[0096] In another preferred embodiment, solvent B is selected from the following group: pyridine, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, acetone, or a combination thereof.

[0097] In another preferred embodiment, in step 3-1), the ratio of the mass of the compound to the volume of solvent B is 50-300 mg / ml, preferably 70-200 mg / ml.

[0098] In another preferred embodiment, solvent C is selected from the following group: isopropyl ether, ethanol, or a combination thereof.

[0099] In another preferred embodiment, in method three, the ratio of the mass of the compound to the volume of solvent C is 5-100 mg / ml, preferably 10-80 mg / ml.

[0100] In another preferred embodiment, in step 4-1), the ratio of the mass of the compound to the volume of 1,4-dioxane is 50-200 mg / ml, preferably 80-150 mg / ml.

[0101] In another preferred embodiment, in step 4-2), the stirring rate is 10-200 rpm / min, preferably 80-120 rpm / min.

[0102] In another preferred embodiment, in step 5-1), the ratio of the mass of the amorphous phase to the volume of the chloroform solvent is 40-120 mg / ml, preferably 50-100 mg / ml.

[0103] In another preferred embodiment, the solvent D is selected from the following group: dichloromethane, 1,2-dichloroethane, or a combination thereof.

[0104] In another preferred embodiment, in step 6-1), the ratio of the mass of the compound to the volume of the solvent D is 50-200 mg / ml, preferably 80-150 mg / ml.

[0105] In another preferred embodiment, in method six, the ratio of the mass of the compound to the volume of isopropyl ether is 20-100 mg / ml, preferably 40-60 mg / ml.

[0106] In another preferred embodiment, in step 7-1), the ratio of the mass of the amorphous phase to the volume of toluene is 15-50 mg / ml, preferably 20-40 mg / ml.

[0107] In another preferred embodiment, in step 8-1), the ratio of the mass of the compound to the volume of acetone is 50-200 mg / ml, preferably 80-150 mg / ml.

[0108] In another preferred embodiment, in method eight, the ratio of the mass of the compound to the volume of ethylene glycol is 5-50 mg / ml, preferably 10-30 mg / ml.

[0109] In another preferred embodiment, the amorphous form is prepared by a method selected from the group consisting of: heating method, rotary evaporation method, and freeze-drying method.

[0110] In another preferred embodiment, the heating method comprises the following steps:

[0111] a-1) providing a compound represented by formula (I);

[0112] a-2) heating the compound at 160-200° C. (preferably 170-190° C.) for 0.1-5 h, and cooling at -10-20° C. to obtain the amorphous form.

[0113] In another preferred embodiment, the rotary evaporation method comprises the following steps:

[0114] b-1) providing a first mixed solution, wherein the first mixed solution comprises a compound represented by formula (I) and a first solvent;

[0115] b-2) rotary evaporating the first mixed solution to obtain the amorphous phase.

[0116] In another preferred embodiment, the first solvent is selected from the following group: methanol and ethanol.

[0117] In another preferred embodiment, in the first mixed solution, the concentration of the compound represented by formula (I) is 0.01 g / L to 13.3 g / L.

[0118] In another preferred embodiment, in step b-2), the rotary evaporation is carried out at 0-60°C, preferably 10-55°C, more preferably 20-50°C.

[0119] In another preferred embodiment, the freeze-drying method comprises the following steps:

[0120] c-1) providing a second mixed solution, wherein the second mixed solution comprises a compound represented by formula (I) and a second solvent;

[0121] c-2) freezing the second mixed solution at a first treatment temperature for a first time;

[0122] c-3) freeze-drying the product obtained in step c-2) at a second treatment temperature for a second time to obtain the amorphous form.

[0123] In another preferred embodiment, the second solvent is a halogenated alkane solvent.

[0124] In another preferred embodiment, the second solvent is selected from the following group: chloroform, dichloromethane, 1,2-dichloroethane, or a combination thereof.

[0125] In another preferred embodiment, in the second mixed solution, the concentration of the compound represented by formula (I) is 0.01 g / L to 40.0 g / L, preferably 0.1-35 g / L, and more preferably 1-30 g / L.

[0126] In another preferred embodiment, the first treatment temperature is -100 to -20°C, or only -90 to -60°C.

[0127] In another preferred embodiment, the first time is 5-24 hours, preferably 10-16 hours.

[0128] In another preferred embodiment, the second treatment temperature is -60 to -20°C, preferably -55 to -40°C.

[0129] In another preferred embodiment, the second time is 2-24 hours, preferably 4-12 hours.

[0130] The fourth aspect of the present invention provides a use of the polymorph described in the first aspect of the present invention for preparing an anti-plant virus agent.

[0131] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0132] Figure 1 The XRD pattern of Form B obtained in Example 1 is shown.

[0133] Figure 2 The DSC graph of Form B obtained in Example 1 is shown.

[0134] Figure 3 The TG diagram of the crystalline form B obtained in Example 1 is shown.

[0135] Figure 4 The quantitative analysis standard curve of Form B obtained in Example 1 is shown.

[0136] Figure 5 The XRD pattern of the crystal form A obtained in Comparative Example 1 is shown.

[0137] Figure 6 The DSC graph of Form A obtained in Comparative Example 1 is shown.

[0138] Figure 7 The TG diagram of the crystalline form A obtained in Comparative Example 1 is shown.

[0139] Figure 8 The five-day high temperature stability XRD spectrum of Form B obtained in Example 1 is shown.

[0140] Fig. 9 The XRD spectrum of the high temperature stability of Form B obtained in Example 1 for ten days is shown.

[0141] Fig.10 The five-day high-humidity stability XRD spectrum of Form B obtained in Example 1 is shown.

[0142] Fig.11 The XRD spectrum of the ten-day high-humidity stability of Form B obtained in Example 1 is shown.

[0143] Fig.12 The five-day light stability XRD spectrum of Form B obtained in Example 1 is shown.

[0144] Fig.13 The XRD spectrum of the ten-day light stability of Form B obtained in Example 1 is shown.

[0145] Fig.14 The XRD pattern of the amorphous product obtained by the melting method in Example 2 is shown.

[0146] Fig.15 The XRD pattern of the amorphous material obtained by rotary evaporation in Example 3 is shown.

[0147] Fig.16 The XRD pattern of the amorphous product obtained by freeze-drying in Example 4 is shown.

[0148] Fig.17 The XRD pattern of Form C obtained in Example 5 is shown.

[0149] Fig.18 The DSC graph of Form C obtained in Example 5 is shown.

[0150] Fig.19 The TG diagram of the crystal form C obtained in Example 5 is shown.

[0151] Fig. 20 The XRD pattern of Form D obtained in Example 6 is shown.

[0152] Fig.21 The DSC graph of Form D obtained in Example 6 is shown.

[0153] Fig. 22 The TG chart of the crystal form D obtained in Example 6 is shown.

[0154] Fig.23 The XRD pattern of Form E obtained in Example 7 is shown.

[0155] Fig.24 The DSC graph of Form E obtained in Example 7 is shown.

[0156] Fig.25 The TG chart of Form E obtained in Example 7 is shown.

[0157] Fig.26 The XRD pattern of Form F obtained in Example 8 is shown.

[0158] Fig. 27 The DSC graph of Form F obtained in Example 8 is shown.

[0159] Fig.28 The TG chart of Form F obtained in Example 8 is shown. DETAILED DESCRIPTION

[0160] After long-term and in-depth research, the inventor unexpectedly prepared a polymorph of chlorpyrifos with excellent solubility and stability by improving the process. On this basis, the inventor completed the present invention.

[0161] the term

[0162] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0163] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0164] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0165] Compounds of formula I

[0166] The compound of formula I of the present invention is chlorpyrifos, and its structural formula is The chemical name is N-[2-(4-methylbenzothiazolyl)]-2-amino-2'-fluorophenyl-O,O-diethylphosphonate. This compound is a novel antiviral agent of fluorinated aminophosphonates. This agent is environmentally friendly, has a simple production process, does not pollute the three wastes, and can also improve the disease resistance of plants. It has a good control effect on rice black streaked dwarf disease and tomato virus disease.

[0167] Polymorph

[0168] Polymorphic forms of a compound can exhibit different melting points, hygroscopicity, stability, solubility, bioavailability and flowability, which are important factors affecting drugability.

[0169] Solvate

[0170] During the contact between a compound or drug molecule and a solvent molecule, it is inevitable that the solvent molecule and the compound molecule form a eutectic and remain in the solid substance due to external and internal conditions. The substance formed after the drug and the solvent crystallize is called a solvate.

[0171] Pesticide composition

[0172] The "active ingredient" in the pesticide composition of the present invention refers to the compound of formula (I) described in the present invention.

[0173] The "active ingredients" and pesticide compositions described in the present invention can be used to prevent or control harmful organisms.

[0174] In another preferred embodiment, the "pesticide-acceptable carrier" refers to a wetting agent, an emulsifier, a dispersant, a sticker, a stabilizer, a synergist, and the like.

[0175] Preparation method

[0176] When preparing the crystal form B, the present invention uses a heating method, which is easy to quickly and mass industrially produce and has a high yield.

[0177] When preparing the crystal form C, the present invention uses a suspension and dissolution method that is easy for industrial production.

[0178] When preparing the crystal form D in the present invention, a suspension stirring method is used, which is simple and easy to implement and easy to industrialize.

[0179] When preparing the crystal form E in the present invention, a dissolution and ultrasonic method is used, which is simple and easy to perform and is easy for industrial production.

[0180] When preparing the crystal form F in the present invention, a dissolution and ultrasonic method is used, which is simple and easy to perform and is easy for industrial production.

[0181] The invention uses a heating method to prepare the amorphous material, which is simple and easy to operate.

[0182] use

[0183] The present invention provides uses of crystal forms B, C, D, E and F and pesticide compositions thereof, which have the functions of activating crop salicylic acid conduction, enhancing antiviral ability, improving plant disease resistance, and having good control effects on rice black streaked dwarf disease and tomato virus disease.

[0184] Compared with the prior art, the present invention has the following main advantages:

[0185] (1) The crystalline form of the present invention has good stability and non-hygroscopicity, and is superior to the existing crystalline form A in solubility experiments.

[0186] (2) The crystal preparation method of the present invention is simple and suitable for large-scale industrial production.

[0187] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not specified in the following examples are usually performed under conventional conditions or under conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0188] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.

[0189] Test method:

[0190] XRD (X-ray powder diffraction) method: Instrument model: Rigaku Ultima IV, target: Cu-K (40 kV, 40 mA), D / tex Ultra detector was used at room temperature. The scanning range was from 3° to 45° in 2 intervals, and the scanning speed was 20° / min.

[0191] The measurement differences associated with such X-ray powder diffraction analysis results are caused by a variety of factors including: (a) errors in sample preparation (e.g., sample height), (b) instrument errors, (c) calibration differences, (d) operator errors (including errors in determining peak positions), and (e) the nature of the material (e.g., preferred orientation errors). Calibration errors and sample height errors often result in displacements of all peaks in the same direction. When a flat support is used, small differences in sample height will result in large displacements of XRD peak positions. Systematic studies have shown that sample height differences of 1 mm can result in peak displacements of up to 1° of 2θ. These displacements can be identified from the X-ray diffraction pattern and can be eliminated by compensating for the displacements (applying the system calibration factor to all peak position values) or recalibrating the instrument. As described above, by applying the system calibration factor to make the peak positions consistent, measurement errors from different instruments can be corrected.

[0192] TG (thermogravimetric analysis) method: Instrument model: TA Q500 thermogravimetric analyzer, using N2 atmosphere, heating rate of 10°C / min.

[0193] DSC (Differential Scanning Calorimetry) method: Instrument model: TA Q2000, using N2 atmosphere, heating rate of 10°C / min.

[0194] Purity: (1) Pass the Form I and Form II samples through a 100-mesh sieve, compare the powder diffraction spectra of Form I and Form II, and select appropriate characteristic peaks for quantitative analysis. (2) Weigh 60 mg of Form I and Form II after passing through a 100-mesh sieve in different proportions, mix them thoroughly using the equal amount addition method, divide them into three parts, and measure them by XRPD. The measurement conditions of XRPD are the same as those in step 1, and the characteristic peak intensity is the average of the three measurement results. (3) By calculating the mass fraction ratio of Form II in the sample and the relative characteristic peak intensity ratio of Form II in the sample, a linear regression is performed to obtain a standard curve, and the reliability of the standard curve is evaluated by the size of the correlation coefficient R2. (4) Reconfigure the Form II samples with different mass ratios, keep the total amount at about 20 mg, and perform XRPD measurement. The relative error between the value of Form II content and the actual Form II content obtained by quantitative standard curve analysis further verifies the accuracy of the standard curve. (5) Determination of the detection limit of the XRPD quantitative method: The detection lower limit is determined by comparing the peak height of the characteristic peak and the relative error between the mass fraction of the II crystal form calculated and the actual value.

[0195] Example 1 Preparation of Form B

[0196] Weigh 1.0 g of amorphous chlorpyrifos in a container, heat to 157° C., keep warm for 30 minutes, then naturally cool to room temperature and solidify to obtain chlorpyrifos crystal form B.

[0197] The XRD pattern of the obtained crystal form B is shown in Figure 1 The diffraction angle data are basically shown in Table 1 below.

[0198] Table 1. XRD data of Form B

[0199] 2-Theta d(A) I(Height)% 8.7 10.2043 20 9.3 9.541 15.1 9.8 9.0535 4.2 11.9 7.431 91.5 12.5 7.0522 10.6 12.9 6.8781 13.7 13.3 6.6313 2.5 14.9 5.9248 100 16.2 5.4808 29.8 17.3 5.1217 56.7 18.0 4.9352 8.8 18.4 4.8277 9.8 18.9 4.6818 17.4 19.8 4.4849 23 20.3 4.3666 46.3 21.4 4.1526 22.9 22.0 4.0369 5.1 22.4 3.9588 84.6 22.7 3.9071 46.4 24.1 3.6951 9.9 24.8 3.5904 3.6 25.2 3.526 3.7 26.4 3.3729 14.2 27.1 3.2854 12.1

[0200] The DSC spectrum of Form B is basically as follows Figure 2 As shown, the endothermic peak corresponds to the melting process.

[0201] The TG spectrum of Form B is basically as follows Figure 3 As shown, there is essentially no weight loss before decomposition.

[0202] Purity determination of Form B: By comparing the powder diffraction patterns of Form A and Form B, select the characteristic peaks for quantitative analysis, and select the characteristic peak height to represent the characteristic peak intensity. The characteristic peak diffraction angle of Form A is 10.34 ± 0.1°, and its peak height is expressed as A 10.34 Relative strength 1576 is the peak height of the diffraction angle of 10.34° in the XRPD diffraction pattern of 20 mg pure crystal form I. The characteristic diffraction peak of crystal form B has a diffraction angle of 8.858±0.1°, and its peak height is expressed as A 8.858 Relative strength 1096 is the peak height of the diffraction angle of 8.858° in the XRPD diffraction pattern of 20 mg pure crystal form B. The relative intensity of the characteristic peak of crystal form B in the mixed crystal is Relative error is the experimental value, is the calculated value.

[0203] Mixed crystals with different contents of form B 8.858 ,I 10.34 and I hB The values ​​are shown in Table 1. When the content of Form B is less than 10% or greater than 90%, the relative error is greater than 5%, and this part of the data cannot be used for quantitative analysis. This is due to the detection limit of XRPD technology in the quantitative process of the drug crystal form. When the content of Form B is greater than 10%, it can be more accurately detected in XRPD, so the quantitative lower limit of the standard curve of Form B is 10% and the upper limit is 90%. The standard curve is as follows Figure 4 .

[0204] Table 2 Mixed crystals with different crystalline content I 8.858 ,I 10.34 and I hB

[0205]

[0206] The standard curve equation is: Y = 106.27x-4.815, the correlation coefficient R 2 =0.9904, when the content of form B is between 10% and 90%, the relative error is less than 5%, which can be used as a quantitative analysis of the mixed crystals of form A and form B.

[0207] Comparative Example 1 Preparation of Form A

[0208] According to the preparation method of patent CN1291993C, crystal form A was obtained by recrystallization in ethanol.

[0209] The XRD pattern of the obtained crystal form A is shown in Figure 5 The diffraction angle data are basically shown in Table 3 below.

[0210] Table 3. XRD data of Form A

[0211]

[0212]

[0213] The DSC spectrum of Form A is basically as follows Figure 6 As shown, the endothermic peak corresponds to the melting process.

[0214] The TG spectrum of Form A is basically as follows Figure 7 As shown, there is essentially no weight loss before decomposition.

[0215] Stability study of Form B

[0216] High temperature stability

[0217] The Form B sample in Example 1 was placed in a 60°C oven, and after 5 and 10 days, the sample was taken out for XRD testing to examine the crystal stability of the sample to temperature. Figure 8 , Fig. 9 As shown, the Form B sample is stable under this condition.

[0218] High humidity stability

[0219] The crystal form B sample in Example 1 was placed under 92.5% humidity conditions, and the sample was taken out for XRD testing after 5 and 10 days to examine the crystal form stability of the sample to humidity. The results are as follows: Fig.10 , Fig.11 As shown, the Form B sample is stable under this condition.

[0220] Light stability

[0221] The Form B sample in Example 1 was placed under a light intensity of 4500 lux, and the sample was taken out for XRD testing after 5 and 10 days to examine the crystal stability of the sample under light. Fig.12 , Fig.13 As shown, the Form B sample is stable under this condition.

[0222] Comparison of solubility of Form A and Form B

[0223] Form A is Compound I. According to the preparation method in the original compound patent CN1291993C, the prepared crystal form is named Form A.

[0224] Excessive amounts of Form A and Form B were weighed and suspended in n-hexane, xylene, 1,2-dichloroethane, ethyl acetate, acetone, methanol solvent and water, respectively, and shaken for 24 hours. After standing for 2 hours, the supernatant was filtered and the solubility was tested by ultra-high performance liquid chromatography. Waters ACQUITY BEH C18 column (2.1×50mm, id1.7μm) reverse phase chromatography column, detection wavelength: 270nm, detection temperature: 25℃, injection volume: 2μL, mobile phase: methanol / water=80 / 20 (v / v). The test results are as follows:

[0225] Table 4. Comparison of solubility of Form A and Form B

[0226]

[0227] It can be concluded that except for a slight improvement in xylene, the solubility of Form B in the other six solvents is significantly greater than that of Form A.

[0228] In the present invention, the amorphous phosphine used is prepared by the following method:

[0229] Example 2 Preparation of amorphous phosphofluoride by melting method

[0230] Weigh 1.0 g of phosphofluoride into a container, heat to 180°C, keep warm for 30 minutes, and immediately cool in an ice bath at 4°C to solidify to obtain an amorphous form.

[0231] The XRD pattern of the obtained amorphous Fig.14 , the spectrum shows amorphous.

[0232] Example 3 Preparation of amorphous phosphofluoride by rotary evaporation

[0233] Weigh 40 mg of phosphofluoride into a container, dissolve it in 3.0 mL of methanol solvent at room temperature, and rotary evaporate after the solution becomes clear at a rotary evaporation temperature of 40° C. to obtain an amorphous form.

[0234] The XRD pattern of the obtained amorphous Fig.15 , the spectrum shows amorphous.

[0235] Example 4 Preparation of amorphous phosphofluoride by freeze drying

[0236] Weigh 10 mg of phosphofluoride into a container, add 0.5 mL of 1,2-dichloroethane solvent, freeze at -80°C for 12 h, take out and dry in a freeze dryer at -50°C for 6 h to obtain an amorphous form.

[0237] The XRD pattern of the obtained amorphous Fig.16 , the spectrum shows amorphous.

[0238] Example 5 Preparation of Form C

[0239] Method 1: Weigh 200 mg of amorphous phosphine difluoride into a container, add 1 ml of ethanol, suspend at room temperature for 10 minutes, filter and vacuum dry the solid to obtain Form C.

[0240] Method 2: Weigh 40 mg of chlorpyrifos and dissolve it in 0.5 ml of pyridine, then add it to 2.5 ml of isopropyl ether solvent, stand at room temperature for evaporation, and vacuum dry the solid to obtain Form C.

[0241] Method 3: Weigh 40 mg of chlorpyrifos and dissolve it in 0.4 ml of dichloromethane, then add it to 0.8 ml of ethanol solvent, let it stand at 4°C for evaporation, and vacuum dry the solid to obtain Form C.

[0242] Method 4: Weigh 40 mg of phosphofluoride and dissolve it in 0.4 ml of 1,2-dichloroethane, then add it to 2.0 ml of isopropyl ether solvent, stand at room temperature for evaporation, and vacuum dry the solid to obtain Form C.

[0243] The XRD pattern of the obtained crystal form C is shown in Fig.17 , the diffraction angle data are basically shown in Table 5 below.

[0244] Table 5 XRD diffraction angle data of Form C

[0245]

[0246]

[0247] The DSC spectrum of Form C is basically as follows Fig.18 As shown, the endothermic peak corresponds to the melting decomposition process.

[0248] The TG spectrum of Form C is basically as follows Fig.19As shown, there is essentially no weight loss before decomposition.

[0249] Example 6 Preparation of Form D

[0250] Weigh 200 mg of chlorpyrifos into a container, add 2 ml of 1,4-dioxane solvent (yield 93%), suspend and stir at room temperature for 12 h, filter and vacuum dry the solid to obtain Form D.

[0251] The XRD pattern of the obtained crystal form D is basically as follows Fig. 20 As shown, the diffraction angle data is basically as shown in Table 6 below.

[0252] Table 6 XRD data of Form D

[0253]

[0254]

[0255] The DSC spectrum of Form D is basically as follows Fig.21 As shown, the first endothermic peak corresponds to the desolvation process, and the second endothermic peak corresponds to the melting decomposition process.

[0256] The TG spectrum of Form D is basically as follows Fig. 22 As shown, the weight loss of about 11.39% before 150°C is due to the solvent loss process. It can be determined that Form D is a 1,4-dioxane solvate.

[0257] Example 7 Preparation of Form E

[0258] Method 1: Weigh 40 mg of amorphous phosphonium chloride into a container, add 0.5 ml of chloroform, sonicate for 1 hour, let stand for evaporation, and vacuum dry to obtain Form E.

[0259] Method 2: Weigh 40 mg of phosphofluoride and dissolve it in 0.4 ml of 1,2-dichloroethane, then add it to 0.8 ml of isopropyl ether solvent, stand it at room temperature for evaporation, and vacuum dry the solid to obtain Form E.

[0260] The XRD pattern of the obtained crystal form E is basically as follows Fig.23 As shown, the diffraction angle data is basically as shown in Table 7 below.

[0261] Table 7 XRD data of Form E

[0262]

[0263]

[0264] The DSC spectrum of Form E is basically as follows Fig.24As shown, the first endothermic peak corresponds to the melting decomposition process, followed by the second endothermic peak of crystal transformation, which is type C (i.e., crystal form C), and the third endothermic peak corresponds to type B (i.e., crystal form B).

[0265] The TG spectrum of Form E is basically as follows Fig.25 As shown, there is essentially no weight loss before decomposition.

[0266] Example 8 Preparation of Form F

[0267] Method 1: Weigh 40 mg of amorphous phosphine into a container, add 1.5 ml of toluene, sonicate for 1 hour, let stand for evaporation, and vacuum dry to obtain Form F.

[0268] Method 2: Weigh 40 mg of chlorpyrifos and dissolve it in 0.4 ml of acetone solvent, then add it to 2.0 ml of ethylene glycol, let it stand at room temperature, filter it, and then vacuum dry it to obtain Form F.

[0269] The XRD pattern of the obtained crystal form F is basically as follows Fig.26 As shown, the diffraction angle data is basically as shown in Table 8 below.

[0270] Table 8 XRD data of Form F

[0271]

[0272]

[0273] The DSC spectrum of Form F is basically as follows Fig. 27 As shown, the endothermic peak corresponds to the melting decomposition process.

[0274] The TG spectrum of Form F is basically as follows Fig.28 As shown, there is essentially no weight loss before decomposition.

[0275] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A method for preparing the crystalline form B of the compound represented by formula (I), characterized in that: The method comprises the steps of: (I) 1-1) Weighing the amorphous form of the compound represented by formula (I); 1-2) heating the amorphous phase to 150-160° C., keeping the temperature, and then naturally cooling to room temperature and solidifying to obtain the crystalline form B; The X-ray powder diffraction pattern of the crystalline form B has diffraction peaks at the following 2θ values: 11.9±0.2°, 14.9±0.2°, 17.3±0.2°, 20.3±0.2°, 22.4±0.2°, and 22.7±0.2°.

2. The method according to claim 1, characterized in that The amorphous form is prepared by a method selected from the group consisting of a heating method, a rotary evaporation method, and a freeze-drying method.

3. The method according to claim 1, characterized in that The crystalline form B has one or more characteristics selected from the following group: 1) The X-ray powder diffraction pattern of the crystalline form B is substantially as shown in FIG1 ; 2) The DSC graph of the crystal form B has an endothermic peak in the range of 155 to 165°C; 3) The DSC graph of the crystal form B is basically as shown in Figure 2; 4) The TG graph of the crystal form B is basically as shown in FIG3 ; 5) At 25°C, the solubility of the crystalline form B in n-hexane is ≥1 mg / mL.